Belimumab
| Evidence Level: L5 | Predicted Indications: 52 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Belimumab |
| DrugBank ID | DB08879 |
| Brand Names (EU) | Benlysta |
| Evidence Level | L5 |
| Predicted Indications | 52 |
| Top Prediction Score | 99.96% |
Approved Indication (EMA)
Benlysta is indicated as add-on therapy in patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti‑dsDNA and low complement) despite standard therapy. Benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.Benlysta is indicated as add-on therapy in adult patients with active, autoantibody-posi
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | primary release disorder of platelets | 99.96% | DL |
| 2 | pseudo-von Willebrand disease | 99.96% | DL |
| 3 | Glanzmann thrombasthenia | 99.88% | DL |
| 4 | fetal and neonatal alloimmune thrombocytopenia | 99.59% | DL |
| 5 | severe nonproliferative diabetic retinopathy | 99.05% | DL |
| 6 | autosomal dominant macrothrombocytopenia | 99.04% | DL |
| 7 | granulomatous disease, chronic, autosomal recessive, 5 | 97.91% | DL |
| 8 | anus disease | 97.89% | DL |
| 9 | inflammatory bowel disease | 97.76% | DL |
| 10 | granulomatous disease with defect in neutrophil chemotaxis | 97.71% | DL |
| 11 | Scott syndrome | 97.42% | DL |
| 12 | functional neutrophil defect | 97.15% | DL |
| 13 | congenital hypotrichosis with juvenile macular dystrophy | 97.05% | DL |
| 14 | systemic sclerosis | 96.72% | DL |
| 15 | psoriasis | 96.70% | DL |
| 16 | bleeding diathesis due to a collagen receptor defect | 96.67% | DL |
| 17 | hemorrhagic disorder due to a constitutional thrombocytopenia | 96.63% | DL |
| 18 | Crohn disease of the esophagus | 96.51% | DL |
| 19 | ulcerative colitis (disease) | 96.50% | DL |
| 20 | cyclic hematopoiesis | 96.05% | DL |
Showing top 20 of 52 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.